Free Trial

Coherus Oncology (CHRS) Competitors

Coherus Oncology logo
$1.65 -0.02 (-1.20%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$1.64 -0.01 (-0.61%)
As of 10/24/2025 07:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CHRS vs. NRIX, KOD, DAWN, TERN, PRME, TBPH, AQST, GHRS, ARVN, and ERAS

Should you be buying Coherus Oncology stock or one of its competitors? The main competitors of Coherus Oncology include Nurix Therapeutics (NRIX), Kodiak Sciences (KOD), Day One Biopharmaceuticals (DAWN), Terns Pharmaceuticals (TERN), Prime Medicine (PRME), Theravance Biopharma (TBPH), Aquestive Therapeutics (AQST), GH Research (GHRS), Arvinas (ARVN), and Erasca (ERAS). These companies are all part of the "pharmaceutical products" industry.

Coherus Oncology vs. Its Competitors

Coherus Oncology (NASDAQ:CHRS) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

72.8% of Coherus Oncology shares are owned by institutional investors. 8.1% of Coherus Oncology shares are owned by insiders. Comparatively, 7.4% of Nurix Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Nurix Therapeutics had 24 more articles in the media than Coherus Oncology. MarketBeat recorded 28 mentions for Nurix Therapeutics and 4 mentions for Coherus Oncology. Coherus Oncology's average media sentiment score of 0.62 beat Nurix Therapeutics' score of 0.13 indicating that Coherus Oncology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Coherus Oncology
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Nurix Therapeutics
2 Very Positive mention(s)
4 Positive mention(s)
12 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

Coherus Oncology has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coherus Oncology$266.96M0.72$28.51M$1.551.06
Nurix Therapeutics$54.55M15.63-$193.57M-$2.97-3.73

Coherus Oncology currently has a consensus target price of $4.51, indicating a potential upside of 173.48%. Nurix Therapeutics has a consensus target price of $27.07, indicating a potential upside of 144.06%. Given Coherus Oncology's higher possible upside, analysts plainly believe Coherus Oncology is more favorable than Nurix Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coherus Oncology
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Nurix Therapeutics
1 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
2 Strong Buy rating(s)
2.83

Coherus Oncology has a net margin of 125.90% compared to Nurix Therapeutics' net margin of -292.50%. Coherus Oncology's return on equity of 0.00% beat Nurix Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Coherus Oncology125.90% N/A -34.85%
Nurix Therapeutics -292.50%-53.57%-40.82%

Coherus Oncology has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.33, suggesting that its share price is 133% more volatile than the S&P 500.

Summary

Coherus Oncology beats Nurix Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Coherus Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CHRS vs. The Competition

MetricCoherus OncologyMED IndustryMedical SectorNASDAQ Exchange
Market Cap$194.10M$3.43B$6.23B$10.66B
Dividend YieldN/A2.27%5.71%4.82%
P/E Ratio1.0624.2730.2030.21
Price / Sales0.72489.03590.34132.63
Price / Cash5.7345.5737.0161.44
Price / Book-1.4510.4012.046.60
Net Income$28.51M-$52.62M$3.32B$276.82M
7 Day PerformanceN/A2.09%1.89%2.58%
1 Month Performance13.79%12.32%7.68%3.76%
1 Year Performance110.46%14.12%56.01%33.84%

Coherus Oncology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CHRS
Coherus Oncology
4.2051 of 5 stars
$1.65
-1.2%
$4.51
+173.5%
+107.8%$194.10M$266.96M1.06330News Coverage
Analyst Forecast
NRIX
Nurix Therapeutics
1.9634 of 5 stars
$10.39
+5.6%
$27.79
+167.4%
-56.0%$756.53M$54.55M-3.50300Trending News
Analyst Forecast
Gap Up
KOD
Kodiak Sciences
3.1985 of 5 stars
$17.70
+25.5%
$13.20
-25.4%
+444.9%$744.79MN/A-4.6690Trending News
Analyst Forecast
Gap Up
DAWN
Day One Biopharmaceuticals
3.1635 of 5 stars
$7.41
+2.9%
$25.29
+241.2%
-48.2%$737.51M$131.16M-7.8060
TERN
Terns Pharmaceuticals
3.9353 of 5 stars
$8.62
+2.5%
$16.24
+88.4%
+15.1%$735.97MN/A-8.2940News Coverage
Analyst Forecast
PRME
Prime Medicine
0.4944 of 5 stars
$6.18
+13.4%
N/AN/A$733.43M$2.98M-3.96N/ANews Coverage
Analyst Upgrade
Gap Up
TBPH
Theravance Biopharma
2.2159 of 5 stars
$14.31
+0.4%
$23.00
+60.7%
+65.3%$718.15M$64.38M59.63110
AQST
Aquestive Therapeutics
2.7106 of 5 stars
$7.49
+5.8%
$10.71
+43.0%
+24.8%$706.04M$57.56M-10.70160Positive News
Analyst Forecast
GHRS
GH Research
2.5719 of 5 stars
$14.00
+3.8%
$30.38
+117.0%
+84.8%$701.86MN/A-18.9210Gap Up
ARVN
Arvinas
3.6259 of 5 stars
$9.72
+2.1%
$16.18
+66.5%
-65.8%$698.94M$263.40M-9.62420News Coverage
Upcoming Earnings
Analyst Forecast
ERAS
Erasca
3.2196 of 5 stars
$2.46
+1.7%
$3.75
+52.4%
-7.8%$686.48MN/A-5.47120Gap Up

Related Companies and Tools


This page (NASDAQ:CHRS) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners